drugset / Trial / NCT04973345

Terbutaline Sulfate in Adults With Asthma

NCT04973345

RandomizedCrossoverTriple-blindTreatment

Summary

The overall aim in Part 1 is to compare the pharmacokinetic (PK)/pharmacodynamics (PD) relationship in intravenous (IV) versus subcutaneous (SQ) terbutaline sulfate to identify the optimal IV dosing range for use in Part 2. The overall aim in Part 2 is to evaluate the optimal IV dosing of terbutaline sulfate based on PD response and safety data.

Timeline

Start
2023-07-07
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Terbutaline Small molecule 0.1 mg Intravenous
Subject Terbutaline Small molecule 0.25 mg Intravenous
Subject Terbutaline Small molecule 0.5 mg Intravenous
Subject Terbutaline Small molecule 1 mg Intravenous

Indications